Voice biomarkers are a powerful tool in the world of healthcare and clinical research. When a person encounters a medical condition, different organs and parts of the body are impacted including the brain, lungs, heart, muscles, and vocal cords. The healthcare system...
The FDA recently approved Leqembi, a new drug by Eisai that has been shown in clinical studies to slow the cognitive decline associated with Alzheimer’s Disease. This approval marks a major milestone in the fight against dementia, as Leqembi is the first drug...
Measuring respiratory function is important. It’s used to inform COPD or asthma diagnosis, track disease progression, and help clinicians make ventilatory support decisions in diseases that impact respiration, such as amyotrophic lateral sclerosis (ALS). These...
Researchers from Aural Analytics, Inc., Arizona State University, and the University of Wisconsin School of Medicine and Public Health presented new research connecting speech to dementia at the Alzheimer’s Association International Conference (AAIC) on July 26-30,...
As the pandemic forces healthcare and pharmaceutical clinical trials to adopt new modes of engaging with patients, the value of digital biomarkers and digital diagnostics is skyrocketing. Speech analytics, in particular, has received significant attention because of...
Without question, one of the most challenging problems in neurodegenerative diseases is the ability to identify the presence of early brain changes, especially before clinical symptoms appear. This ability is key to developing and testing neuroprotective or even...